EUCTR2007-004243-29-NL进行中（未招募）不适用
A Phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) to Raptiva 1mg/kg/week therapy. - Open label trial investigating transition from systemic agents to Raptiva
Merck Serono International SA. An Affiliate of Merck KGaA, Darmstadt, Germany0 个研究点目标入组 182 人开始时间: 2008年5月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion into this study, the subjects must fulfil all of the following criteria:
- •1. Are at least 18 years old.
- •2. Have plaque psoriasis with an sPGA score of at least moderate or severe at time of initiation of previous systemic treatment.
- •3. Are transitioning from methotrexate, cyclosporine, retinoids, PUVA or NBUVB and initiating treatment with Raptiva according to the decision of the investigator and in accordance with the indication and the recommendations of the Raptiva Investigator Brochure, i.e. to which they have failed to respond, have a contraindication to or are intolerant of other systemic therapies.
- •4. Agree to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study.
- •5. Have given written informed consent with the understanding that consent may be withdrawn at any time without prejudice to future medical care.
- •6. Women of childbearing potential must use appropriate contraception during treatment and up to the last study visit (safety follow-up visit). For men, it is also mandatory to practice contraception during participation in the trial, as there are no existing data on the effect of Raptiva on spermatogenesis.
- •7. Discontinuation of any investigational drug or treatment 3 months prior to study start or as per washout requirements from previous protocol.
- •No primary vaccinations (e.g., tetanus, booster, influenza vaccine) for at least 14 days prior to first dose of study drug.For the purposes of this trial, women of childbearing potential is defined as: All female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive.”
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •To be eligible for inclusion into this study, the subjects must not meet any of the following criteria:
- •1. Any contra-indication to Raptiva, according to the Investigator Brochure, or as follows:
- •· Hypersensitivity to Raptiva or to any of the excipients.
- •· Subjects with history of malignancies.
- •· History of active tuberculosis (TB) or currently undergoing treatment for TB. PPD testing or chest X-ray is required for high-risk subjects. Subjects with a positive PPD (not due to BCG vaccination) or chest X-ray will be excluded.
- •· Subjects with specific forms of psoriasis like guttate, erythrodermic or pustular psoriasis as sole or predominant form of psoriasis.
- •· Subjects with immunodeficiencies.
- •2. Simultaneous participation in another clinical trial.
- •3. Subjects experiencing a psoriasis exacerbation during screening period.
- •4. Subjects who have previously been on Raptiva treatment who withdrew due to lack of efficacy or an adverse event. If withdrawal was due to another non-drug reason (vaccination, or infection) then the subject can be included in this study.
- •5. History of hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
- •6. History of thrombocytopenia, haemolytic anaemia or clinically significant anaemia.
- •7. Hepatic enzyme levels =3 times the upper limit of normal or serum creatinine level =2 times the upper limit of normal.
- •8. Pregnant or breast-feeding.
- •9. Any medical condition (prior or existing) that, in the judgment of the investigator or sponsor, could jeopardize the subject’s safety following exposure to study drug.
- •Note: Raptiva should be used with caution in subjects with renal or hepatic impairment.
研究者
相似试验
已完成
4 期
A phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) to Raptiva 1 mg/kg/ week therapy.NL-OMON31969Merck120
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000512-18-Outside-EU/EEAGenzyme Corporation Inc114
招募中
4 期
A collaborative, multicentre, national study for newly diagnosed patients with acute lymphoblastic leukaemiaCTRI/2015/12/006434Tata Medical Center Kolkata
进行中（未招募）
1 期
Will switching HIV-1-infected patients who have drug resistant HIV and stable on a regimen based on a protease inhibitor to another regimen based on the integrase inhibitor bictegravir be as equally effective?Human Immunodeficiency VirusMedDRA version: 20.1Level: LLTClassification code 10008919Term: Chronic HIV infectionSystem Organ Class: 100000004862EUCTR2018-004732-30-GBniversity of Sussex100
进行中（未招募）
1 期
Post-marketing study of safety and efficacy of GARDASIL in young Japanese women.Human Papillomavirus infectionEUCTR2015-002932-42-Outside-EU/EEAMSD K.K., a subsidiary of Merck & Co., Inc1,000